ClinicalTrials.Veeva

Menu

Platelet Activation and Reactivity in Acute Exacerbations of COPD

R

Radboud University Medical Center

Status

Unknown

Conditions

COPD Exacerbation

Treatments

Other: Blood is drawn

Study type

Observational

Funder types

Other

Identifiers

NCT03017625
2016-2847

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of cardiovascular disease. Platelets contribute to acute cardiovascular events and atherosclerosis. When platelets are activated, they form complexes with monocytes. These platelet-monocyte complexes (PMCs) are an early process in atherothrombosis and promote inflammation. In COPD, platelet function in AE-COPD is scarcely studied. This study aims to address this gap by investigating platelet function and coagulation in patients with AE-COPD and after convalescence.

Enrollment

30 estimated patients

Sex

All

Ages

40 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • >40 years
  • Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC < 70% and less than 12% on reversibility testing< Lower limit of normal (LLN))
  • ≥10 pack years of smoking

Exclusion criteria

  • Use of anti-coagulation or other platelet function inhibitors
  • Asthma
  • Chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE)
  • Malignancies

Trial contacts and locations

0

Loading...

Central trial contact

Yvonne F Heijdra, MD, PhD; Floor E Aleva, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems